Drug-eluting stents (DES) have been extremely successful in reducing restenosis and the need for repeat revascularization procedures in patients who undergo PCI. The potential increased incidence of late stent thrombosis prompted cardiologists to prolong the use of dual anti-platelet therapy after the one year duration recommended by the recent ESC guidelines. However, while the premise that the cardiologists should put all their patients on dual clopidogrel-aspirin regimen for life sounds the easy way, it is an unrealistic goal because of the potential increase of bleeding complications and of the healthcare cost increase. The recent possibility to monitor aspirin with bedside assays offers a real opportunity to compare in good aspirin responder patients the two strategies: aspirin-clopidogrel regimen versus mono-aspirin regimen and to respond to the key question: can the investigators switch from dual to single antiplatelet therapy after six months in good aspirin responder patients ? Study National, multicenter, randomised prospective open group comparison of dual clopidogrel-ASA versus single ASA regimen after six months, in good ASA responder patients treated with DES (name: XIENCE) implantation.

End point Primary: At 12 months: death, myocardial infarction, repeat urgent revascularization, stroke requiring a new hospitalisation and major bleedings.

Secondary: Incidence at 24 and 36 months after drug eluting stent(name: XIENCE) implantation, of the same composite endpoint and incidence at 12, 24 and 36 months of minor bleeding complications Participating centres: 60 french centers

Male or female subject ≥ 18 years of age eligible for PCI with at least one drug eluting stent (name: Xience) implanted in all clinical situations excluding primary PCI for acute MI and treatment of the left main artery.

Male or female subject ≥ 18 years of age eligible for PCI with at least one DES Xience.

Patient not pre-treated with protein IIb/IIIa inhibitors (name: abxicimab or eptifibatide) during hospitalization

Patient pre-treated with aspirin and clopidogrel before PCI

ASA check at least 24 hours after the interruption of tirofiban

The subject has given written informed and dated consent to participate in this study.

Exclusion Criteria:

Subjects not able to give informed consent

Prior implantation of DES

Known platelets < 100 000/µl or known hemorrhagic diathesis

Oral anticoagulation or treatment with abxicimab or eptifibatide during hospitalization

ASA check less than 24 hours after the interruption of tirofiban

Thrombolytic therapy within 4 days before ASA check

Contra-indication to aspirin or clopidogrel

Recent major surgery < 6 weeks

Evidence of an active gastrointestinal or urogenital bleeding

Severe liver insufficiency

Primary PCI for acute MI

Left main PCI

Any scheduled surgery during the year after enrollment

Severe concomitant disease with life expectation < two years

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00780156